Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Malta.
Press releases published on August 25, 2025
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar adoption …
Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting
HOUSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced its participation in the 2025 Advances in Genome Biology and Technology (AGBT) Precision Health Conference, …
Husband Material Ministries Announces New Book by Drew Boa: "Outgrow Porn: Find Lasting Freedom Without Fighting an Exhausting Battle—A Man's Guide to Healing"
Colorado Springs, CO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Husband Material Ministries, a leading nonprofit organization dedicated to helping men find lasting freedom from pornography, is proud to announce the release of a groundbreaking new book by its …
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced …
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular …
The Sequoia Project Announces Detailed Agenda of Virtual Data Usability Workshop, Co-Sponsored by AHIMA
VIENNA, Va., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Sequoia Project, a non-profit and trusted advocate for nationwide health IT interoperability, in partnership with the American Health Information Management Association (AHIMA), is releasing the full …
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may …
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary. The campaign reframes what it means to …
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin’s …
Global Suppositories Market to Surpass USD 2.05 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global suppositories market, valued at US$1.56 billion in 2024, stood at US$1.63 billion in 2025 and is projected to advance at a resilient CAGR of 4.7% from 2025 to 2030, culminating in a forecasted …
Global Veterinary Diagnostics Market Set to Reach USD 5.36 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global veterinary diagnostics market, valued at US$3.42 billion in 2024, stood at US$3.68 billion in 2025 and is projected to advance at a resilient CAGR of 7.8% from 2025 to 2030, culminating in a …
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug. 25, 2025 (GLOBE …
Safety Shot Secures $30 Million Strategic Investment From BONK Core Team and FalconX
SCOTTSDALE, AZ, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced it has successfully priced a $30 million financing, anchored by a consortium of strategic investors including FalconX, the …
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, …
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage …
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern …
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new …
Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration (FDA) has …